Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Bone Miner Res ; 39(3): 357-372, 2024 Apr 19.
Article in English | MEDLINE | ID: mdl-38477738

ABSTRACT

Sphingosine-1-phosphate (S1P) plays multiple roles in bone metabolism and regeneration. Here, we have identified a novel S1P-regulated osteoanabolic mechanism functionally connecting osteoblasts (OBs) to the highly specialized bone vasculature. We demonstrate that S1P/S1PR3 signaling in OBs stimulates vascular endothelial growth factor a (VEGFa) expression and secretion to promote bone growth in an autocrine and boost osteogenic H-type differentiation of bone marrow endothelial cells in a paracrine manner. VEGFa-neutralizing antibodies and VEGF receptor inhibition by axitinib abrogated OB growth in vitro and bone formation in male C57BL/6J in vivo following S1P stimulation and S1P lyase inhibition, respectively. Pharmacological S1PR3 inhibition and genetic S1PR3 deficiency suppressed VEGFa production, OB growth in vitro, and inhibited H-type angiogenesis and bone growth in male mice in vivo. Together with previous work on the osteoanabolic functions of S1PR2 and S1PR3, our data suggest that S1P-dependent bone regeneration employs several nonredundant positive feedback loops between OBs and the bone vasculature. The identification of this yet unappreciated aspect of osteoanabolic S1P signaling may have implications for regular bone homeostasis as well as diseases where the bone microvasculature is affected such as age-related osteopenia and posttraumatic bone regeneration.


Sphingosine-1-phosphate (S1P) is a signaling lipid that regulates bone growth and regeneration. In the present study, a novel regenerative mechanism was connected to S1P signaling within the bone. Activation of its receptor S1PR3 in bone-forming osteoblasts led to secretion of vascular endothelial growth factor a (VEGFa), the most potent vessel-stimulating factor. This stimulated the development of specialized vessels of the bone marrow, the H-type vessels, that supported overall bone regeneration. These findings foster our understanding of regular bone metabolism and suggest that S1P-based drugs may help treat diseases such as age-related osteopenia and posttraumatic bone regeneration, conditions crucially dependent on functional bone microvasculature.


Subject(s)
Lysophospholipids , Receptors, Lysosphingolipid , Sphingosine/analogs & derivatives , Vascular Endothelial Growth Factor A , Male , Mice , Animals , Receptors, Lysosphingolipid/metabolism , Sphingosine-1-Phosphate Receptors , Vascular Endothelial Growth Factor A/metabolism , Osteogenesis , Endothelial Cells/metabolism , Mice, Inbred C57BL , Osteoblasts/metabolism
2.
Nat Commun ; 14(1): 8329, 2023 Dec 14.
Article in English | MEDLINE | ID: mdl-38097610

ABSTRACT

Red blood cells (RBC) are the major carriers of sphingosine-1-phosphate (S1P) in blood. Here we show that variations in RBC S1P content achieved by altering S1P synthesis and transport by genetic and pharmacological means regulate glucose uptake and metabolic flux. This is due to S1P-mediated activation of the catalytic protein phosphatase 2 (PP2A) subunit leading to reduction of cell-surface glucose transporters (GLUTs). The mechanism dynamically responds to metabolic cues from the environment by increasing S1P synthesis, enhancing PP2A activity, reducing GLUT phosphorylation and localization, and diminishing glucose uptake in RBC from diabetic mice and humans. Functionally, it protects RBC against lipid peroxidation in hyperglycemia and diabetes by activating the pentose phosphate pathway. Proof of concept is provided by the resistance of mice lacking the S1P exporter MFSD2B to diabetes-induced HbA1c elevation and thiobarbituric acid reactive substances (TBARS) generation in diabetic RBC. This mechanism responds to pharmacological S1P analogues such as fingolimod and may be functional in other insulin-independent tissues making it a promising therapeutic target.


Subject(s)
Diabetes Mellitus, Experimental , Hyperglycemia , Humans , Mice , Animals , Protein Phosphatase 2/genetics , Protein Phosphatase 2/metabolism , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Erythrocytes/metabolism , Hyperglycemia/metabolism , Sphingosine , Lysophospholipids/metabolism , Glucose/metabolism
3.
Int J Mol Sci ; 23(17)2022 08 24.
Article in English | MEDLINE | ID: mdl-36077004

ABSTRACT

Altered plasma sphingosine-1-phosphate (S1P) concentrations are associated with clinical manifestations of atherosclerosis. However, whether long-term elevation of endogenous S1P is pro- or anti-atherogenic remains unclear. Here, we addressed the impact of permanently high S1P levels on atherosclerosis in cholesterol-fed apolipoprotein E-deficient (ApoE-/-) mice over 12 weeks. This was achieved by pharmacological inhibition of the S1P-degrading enzyme S1P lyase with 4-deoxypyridoxine (DOP). DOP treatment dramatically accelerated atherosclerosis development, propagated predominantly unstable plaque phenotypes, and resulted in frequent plaque rupture with atherothrombosis. Macrophages from S1P lyase-inhibited or genetically deficient mice had a defect in cholesterol efflux to apolipoprotein A-I that was accompanied by profoundly downregulated cholesterol transporters ATP-binding cassette transporters ABCA1 and ABCG1. This was dependent on S1P signaling through S1PR3 and resulted in dramatically enhanced atherosclerosis in ApoE-/-/S1PR3-/- mice, where DOP treatment had no additional effect. Thus, high endogenous S1P levels promote atherosclerosis, compromise cholesterol efflux, and cause genuine plaque rupture.


Subject(s)
Atherosclerosis , Plaque, Atherosclerotic , ATP Binding Cassette Transporter 1/genetics , Animals , Apolipoproteins E/genetics , Atherosclerosis/etiology , Cholesterol , Lysophospholipids , Mice , Mice, Knockout , Plaque, Atherosclerotic/complications , Plaque, Atherosclerotic/genetics , Sphingosine/analogs & derivatives
4.
Sci Rep ; 11(1): 4115, 2021 02 18.
Article in English | MEDLINE | ID: mdl-33603041

ABSTRACT

Endometriosis is a painful gynecological condition characterized by ectopic growth of endometrial cells. Little is known about its pathogenesis, which is partially due to a lack of suitable experimental models. Here, we use endometrial stromal (St-T1b), primary endometriotic stromal, epithelial endometriotic (12Z) and co-culture (1:1 St-T1b:12Z) spheroids to mimic the architecture of endometrium, and either collagen I or Matrigel to model ectopic locations. Stromal spheroids, but not single cells, assumed coordinated directional migration followed by matrix remodeling of collagen I on day 5 or 7, resembling ectopic lesions. While generally a higher area fold increase of spheroids occurred on collagen I compared to Matrigel, directional migration was not observed in co-culture or in 12Z cells. The fold increase in area on collagen I was significantly reduced by MMP inhibition in stromal but not 12Z cells. Inhibiting ROCK signalling responsible for actomyosin contraction increased the fold increase of area and metabolic activity compared to untreated controls on Matrigel. The number of protrusions emanating from 12Z spheroids on Matrigel was decreased by microRNA miR-200b and increased by miR-145. This study demonstrates that spheroid assay is a promising pre-clinical tool that can be used to evaluate small molecule drugs and microRNA-based therapeutics for endometriosis.


Subject(s)
Cell Movement/drug effects , Collagen Type I/pharmacology , Endometriosis/drug therapy , Stromal Cells/drug effects , Cell Line , Cell Proliferation/drug effects , Collagen/drug effects , Collagen/metabolism , Drug Combinations , Endometriosis/metabolism , Endometrium/drug effects , Endometrium/metabolism , Female , Humans , Laminin/drug effects , Laminin/metabolism , Matrix Metalloproteinase Inhibitors/pharmacology , MicroRNAs/metabolism , Proteoglycans/drug effects , Proteoglycans/metabolism
5.
Dev Comp Immunol ; 30(8): 699-710, 2006.
Article in English | MEDLINE | ID: mdl-16303181

ABSTRACT

TCR gamma (TRG) chain diversity in splenic gammadelta T cells was determined for an egg-laying mammal (or monotreme), the duckbill platypus. Three distinct V subgroups were found in the expressed TRG chains and these three subgroups are members of a clade not found so far in eutherian mammals or birds. Each subgroup contains approximately five V gene segments, and their overall divergence is much less than is found in eutherians and birds, consistent with their recent evolution from an ancestral V gene segment. The platypus TRG locus also contains three C region genes and many of the residues involved in TCR function, such as interactions with CD3, were conserved in the monotreme C regions. All non-eutherian mammals (monotremes and marsupials) lacked the second cysteine residue necessary to form the intradomain disulfide bond in the C region, a loss apparently due to independent mutations in marsupials and monotremes. Monotreme TRGC regions also had among the most variation in the length of the connecting peptide region described for any species due to repeated motifs.


Subject(s)
Genes, T-Cell Receptor gamma , Platypus/immunology , Receptors, Antigen, T-Cell, gamma-delta/chemistry , Tachyglossidae/immunology , Amino Acid Sequence , Animals , Complementarity Determining Regions , Gene Rearrangement, T-Lymphocyte , Molecular Sequence Data , Phylogeny , Platypus/genetics , Sequence Alignment , Spleen/immunology , Tachyglossidae/genetics
6.
Immunogenetics ; 56(8): 555-63, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15448942

ABSTRACT

Complementary DNAs encoding immunoglobulin light chains were isolated from two monotreme species, Ornithorhynchus anatinus (duckbill platypus) and Tachyglossus aculeatus (echidna). The sequences of both the variable and constant regions of these clones had greater similarity to IGK than to other light chain classes and phylogenetic analyses place them squarely within the mammalian IGK group, establishing them as monotreme IGK homologues. The constant region sequences of all clones were essentially identical within each species and, along with Southern blot results, the data are consistent with a single IGKC in each species. The expressed IGKV repertoires from both platypus and echidna were randomly sampled and there appear to be at least four platypus and at least nine echidna IGKV subgroups. The IGKV subgroups are highly divergent within species, in some cases sharing as little as 57% nucleotide identity. Two of the IGKV subgroups are present in both species, so there is some degree of overlap in the germline repertoires of these two monotremes. Overall the complexity seen in platypus and echidna IGK light chains is comparable with that of other mammals considered to have high levels of germline diversity and is in contrast to what has been found so far for monotreme IGL.


Subject(s)
Immunoglobulin kappa-Chains/genetics , Platypus/immunology , Tachyglossidae/immunology , Amino Acid Sequence , Animals , Base Sequence , Complementarity Determining Regions , Gene Library , Immunoglobulin Constant Regions/genetics , Immunoglobulin Variable Region/genetics , Immunoglobulin kappa-Chains/chemistry , Molecular Sequence Data
SELECTION OF CITATIONS
SEARCH DETAIL
...